UBS Group’s Iterum Therapeutics ITRM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-3,201
| Closed | -$96 | – | 10732 |
|
|
2026
Q1 | $96 | Sell |
3,201
-116,747
| -97% | -$29.3K | ﹤0.01% | 10124 |
|
|
2025
Q4 | $40.2K | Buy |
119,948
+111,322
| +1,291% | +$60K | ﹤0.01% | 7343 |
|
|
2025
Q3 | $5.78K | Sell |
8,626
-173
| -2% | -$136 | ﹤0.01% | 8829 |
|
|
2025
Q2 | $8.76K | Buy |
8,799
+100
| +1% | +$104 | ﹤0.01% | 8926 |
|
|
2025
Q1 | $10.7K | Buy |
8,699
+5,625
| +183% | +$8.34K | ﹤0.01% | 8607 |
|
|
2024
Q4 | $5.44K | Buy |
3,074
+3,073
| +307,300% | +$4.82K | ﹤0.01% | 8661 |
|
|
2024
Q3 | $1 | Hold |
1
| – | – | ﹤0.01% | 9423 |
|
|
2024
Q2 | $1 | Sell |
1
-12,018
| -100% | -$17.4K | ﹤0.01% | 9433 |
|
|
2024
Q1 | $18.5K | Buy |
12,019
+7,070
| +143% | +$11.5K | ﹤0.01% | 6955 |
|
|
2023
Q4 | $9.75K | Buy |
+4,949
| New | +$6.13K | ﹤0.01% | 7471 |
|
|
2023
Q3 | – | Sell |
-48
| Closed | -$51 | – | 9707 |
|
|
2023
Q2 | $51 | Buy |
48
+42
| +700% | +$46 | ﹤0.01% | 8597 |
|
|
2023
Q1 | $6 | Sell |
6
-15,258
| -100% | -$17.6K | ﹤0.01% | 9481 |
|
|
2022
Q4 | $12.8K | Buy |
15,264
+6,943
| +83% | +$9.88K | ﹤0.01% | 8230 |
|
|
2022
Q3 | $13K | Buy |
+8,321
| New | +$25.3K | ﹤0.01% | 8040 |
|
|
2022
Q2 | – | Sell |
-1,966
| Closed | -$7.36K | – | 10615 |
|
|
2022
Q1 | $10K | Sell |
1,966
-2,368
| -55% | -$13.7K | ﹤0.01% | 8417 |
|
|
2021
Q4 | $25K | Buy |
4,334
+3,528
| +438% | +$27.2K | ﹤0.01% | 7586 |
|
|
2021
Q3 | $7K | Sell |
806
-1,143
| -59% | -$14.1K | ﹤0.01% | 8312 |
|
|
2021
Q2 | $68K | Sell |
1,949
-1,582
| -45% | -$34.3K | ﹤0.01% | 6165 |
|
|
2021
Q1 | $75K | Buy |
+3,531
| New | +$84.1K | ﹤0.01% | 6183 |
|
|
2020
Q2 | – | Sell |
-833
| Closed | -$34K | – | 8144 |
|
|
2020
Q1 | $34K | Buy |
833
+703
| +541% | +$29.6K | ﹤0.01% | 6121 |
|
|
2019
Q4 | $9K | Sell |
130
-52
| -29% | -$2.54K | ﹤0.01% | 7335 |
|
|
2019
Q3 | $16K | Buy |
182
+179
| +5,967% | +$17.4K | ﹤0.01% | 6873 |
|
|
2019
Q2 | $0 | Buy |
+3
| New | +$334 | ﹤0.01% | 8002 |
|
|
2019
Q1 | – | Sell |
-9
| Closed | -$1K | – | 7921 |
|
|
2018
Q4 | $1K | Buy |
+9
| New | +$852 | ﹤0.01% | 7896 |
|
Other funds holding ITRM
UBS Group's ITRM Position: Q2 2026 in Review
UBS Group sold out of Iterum Therapeutics (ITRM) in Q2 2026, closing a stake of 3,201 shares — an estimated $96 sold.
UBS Group first reported a position in ITRM in Q4 2018 and held it in 24 quarters. The position peaked at $75K in Q1 2021. 2 funds tracked by Wall St. Rank hold ITRM as of Q2 2026.
- UBS Group reported no remaining Iterum Therapeutics position as of Q2 2026 after selling out during the quarter.
- UBS Group sold 3,201 Iterum Therapeutics shares in Q2 2026, an estimated $96.
- UBS Group first reported a position in Iterum Therapeutics in Q4 2018 and held it in 24 quarters.
- UBS Group's Iterum Therapeutics position peaked at $75K in Q1 2021.
- 2 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.